Spots Global Cancer Trial Database for A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Official Title: An Open-label, Multicenter Phase II Study Evaluating Balstilimab Alone or Balstilimab in Combination With Zalifrelimab in Patients With Advanced Cervical Cancer
Study ID: NCT05033132
Conditions
Study Description
Brief Summary: This is an open-label, multi-center Phase II clinical trial to assess the efficacy, safety, and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination with Zalifrelimab (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Betta Clinical Study Site 4, Bengbu, Anhui, China
Betta Clinical Study Site 2, Hefei, Anhui, China
Betta Clinical Study Site 3, Hefei, Anhui, China
Betta Clinical Study Site 27, Wuhu, Anhui, China
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China
Betta Clinical Study Site 25, Beijing, Beijing, China
Betta Clinical Study Site 42, Chongqing, Chongqing, China
Betta Clinical Study Site 9, Fuzhou, Fujian, China
Betta Clinical Study Site 22, Xiamen, Fujian, China
Betta Clinical Study Site 41, Lanzhou, Gansu, China
Betta Clinical Study Site 39, Lanzhou, Gansu, China
Betta Clinical Study Site 14, Huizhou, Guangdong, China
Betta Clinical Study Site 18, Meizhou, Guangdong, China
Betta Clinical Study Site 10, Zhanjiang, Guangdong, China
Betta Clinical Study Site 11, Nanning, Guangxi, China
Betta Clinical Study Site 5, Cangzhou, Hebei, China
Betta Clinical Study Site 40, Harbin, Heilongjiang, China
Betta Clinical Study Site 43, Wuhan, Hubei, China
Betta Clinical Study Site 28, Wuhan, Hubei, China
Betta Clinical Study Site 12, Wuhan, Hubei, China
Betta Clinical Study Site 29, Wuhan, Hubei, China
Betta Clinical Study Site 31, Xiangyang, Hubei, China
Betta Clinical Study Site 6, Changde, Hunan, China
Betta Clinical Study Site 36, Changsha, Hunan, China
Betta Clinical Study Site 35, Changsha, Hunan, China
Betta Clinical Study Site 13, Changsha, Hunan, China
Betta Clinical Study Site 21, Nanjing, Jiangsu, China
Betta Clinical Study Site 8, Nanjing, Jiangsu, China
Betta Clinical Study Site 38, Ganzhou, Jiangxi, China
Betta Clinical Study Site 19, Nanchang, Jiangxi, China
Betta Clinical Study Site 20, Nanchang, Jiangxi, China
Betta Clinical Study Site 24, Shangrao, Jiangxi, China
Betta Clinical Study Site 16, Changchun, Jilin, China
Betta Clinical Study Site 15, Changchun, Jilin, China
Betta Clinical Study Site 7, Dalian, Liaoning, China
Betta Clinical Study Site 34, Shenyang, Liaoning, China
Betta Clinical Study Site 17, Shenyang, Liaoning, China
Betta Clinical Study Site 30, Xi'an, Shaanxi, China
Betta Clinical Study Site 23, Taiyuan, Shanxi, China
Betta Clinical Study Site 26, Tianjin, Tianjin, China
Betta Clinical Study Site 37, Tianjin, Tianjin, China
Betta Clinical Study Site 32, Ürümqi, Xinjiang, China
Betta Clinical Study Site 33, Hangzhou, Zhejiang, China
Contact Details
Name: Medical Director
Affiliation: Agenus Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
